Mylan Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1961-01-01

Employees: 35K

Market Cap: -

Website: https://www.mylan.com/

Clinical Trials

Therapeutic Equivalence and Safety of Two Econazole Nitrate Cream, 1% Products in Tinea Pedis

Phase 3

Completed

Conditions: Tinea Pedis

Interventions: Drug: Econazole Nitrate Cream, 1%
Drug: Placebo

First Posted Date: 2017-04-26

Last Posted Date: 2022-03-07

Lead Sponsor: Mylan Inc.

Target Recruit Count: 876

Registration Number: NCT03129321

Bioequivalence Study of Pimecrolimus Cream, 1% and Elidel® Cream, 1% in Mild to Moderate Atopic Dermatitis

Phase 3

Completed

Conditions: Atopic Dermatitis

Interventions: Drug: Placebo Cream
Drug: Pimecrolimus Cream, 1%

First Posted Date: 2017-04-11

Last Posted Date: 2022-03-07

Lead Sponsor: Mylan Inc.

Target Recruit Count: 654

Registration Number: NCT03107611

Locations: 🇺🇸
Research Facility 28, Overland Park, Kansas, United States
🇺🇸
Research Facility 1, Miami Lakes, Florida, United States
🇺🇸
Research Facility 6, Boynton Beach, Florida, United States

and more 24 locations

Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD

Phase 3

Completed

Conditions: Low Peak Inspiratory Flow Rate (PIFR)
Chronic Obstructive Pulmonary Disease, COPD

Interventions: Combination Product: Spiriva Handihaler®
Drug: Revefenacin
Drug: Placebo for Spiriva Handihaler®
Drug: Placebo for Revefenacin

First Posted Date: 2017-03-29

Last Posted Date: 2022-02-24

Lead Sponsor: Mylan Inc.

Target Recruit Count: 207

Registration Number: NCT03095456

Locations: 🇺🇸
Clinical Research of Rock Hill, Rock Hill, South Carolina, United States

Effects of TD-4208 on FEV1 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Phase 2

Completed

Conditions: Chronic Obstructive Pulmonary Disease, COPD

Interventions: Drug: Placebo
Drug: TD-4208 700 μg
Drug: TD-4208 350 μg
Drug: Ipratropium 500 μg

First Posted Date: 2017-02-24

Last Posted Date: 2022-02-24

Lead Sponsor: Mylan Inc.

Target Recruit Count: 32

Registration Number: NCT03064113

Locations: 🇳🇿
P3 Research, Wellington, New Zealand

A Survey on Efficacy and Safety in Patients With Endometriosis

Completed

Conditions: Endometriosis

Interventions: Drug: Dydrogesterone

First Posted Date: 2016-10-03

Last Posted Date: 2022-07-06

Lead Sponsor: Mylan Inc.

Target Recruit Count: 60

Registration Number: NCT02921763

Locations: 🇯🇵
Mylan Investigational Site A, Kamigyo-ku, Kyoto, Japan
🇯🇵
Mylan Investigational Site D, Saitama, Iwatsukiku, Japan
🇯🇵
Mylan Investigational Site E, Kyoto, Ukyouku, Japan

and more 12 locations

Thorough QT (TQT) Study of TD-4208 in Healthy Subjects

Phase 1

Completed

Conditions: Cardiac Repolarization in Healthy Subjects

Interventions: Drug: TD-4208 175 mcg
Drug: TD-4208 700 mcg
Drug: Placebo for TD-4208
Drug: Moxifloxacin 400 mg

First Posted Date: 2016-06-30

Last Posted Date: 2022-02-24

Lead Sponsor: Mylan Inc.

Target Recruit Count: 48

Registration Number: NCT02820311

Locations: 🇺🇸
Celerion, Tempe, Arizona, United States

TD-4208 Absorption, Distribution, Metabolism and Excretion (ADME) Study in Healthy Male Subjects

Phase 1

Completed

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Interventions: Drug: TD-4208

First Posted Date: 2016-05-13

Last Posted Date: 2022-02-24

Lead Sponsor: Mylan Inc.

Target Recruit Count: 9

Registration Number: NCT02772159

Locations: 🇺🇸
Celerion, Lincoln, Nebraska, United States

MYL-1401A Efficacy and Safety Comparability Study to Humira®

Phase 3

Completed

Conditions: Arthritis, Psoriatic
Psoriasis

Interventions: Biological: MYL-1401A (Adalimumab)
Biological: Humira® (Adalimumab)

First Posted Date: 2016-03-21

Last Posted Date: 2022-03-11

Lead Sponsor: Mylan Inc.

Target Recruit Count: 294

Registration Number: NCT02714322

Locations: 🇷🇺
Mylan investigational site 156, Kazan, Russian Federation
🇺🇦
Mylan Investigational site 159, Kharkiv, Ukraine
🇺🇦
Mylan investigational site 161, Uzhhorod, Ukraine

and more 30 locations

Extension Study to Assess Safety and Efficacy of Mylan's Insulin Glargine and Lantus® in Type 1 Diabetes Mellitus (T1DM) Patients

Phase 3

Completed

Conditions: Type 1 Diabetes Mellitus

Interventions: Drug: Lantus®
Drug: Mylan's insulin glargine

First Posted Date: 2016-01-28

Last Posted Date: 2022-03-03

Lead Sponsor: Mylan Inc.

Target Recruit Count: 127

Registration Number: NCT02666430

Locations: 🇨🇦
Mylan Investigator Site., Vancouver, British Columbia, Canada
🇸🇰
Mylan Investigator Site, Zilina, Slovakia

Pharmacokinetics of TD-4208 in Patients With Moderate Hepatic Impairment

Phase 1

Completed

Conditions: Hepatic Impairment

Interventions: Drug: TD-4208

First Posted Date: 2015-10-21

Last Posted Date: 2022-02-24

Lead Sponsor: Mylan Inc.

Target Recruit Count: 16

Registration Number: NCT02581592

Locations: 🇺🇸
Orlando Clinical Research Center (OCRD), Orlando, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy